Year: 2025
Type: article
Abstract: Ethical Compliance Statement: UNIFESP—Universidade Federal de São Paulo Ethics Committee approved this study. The patient consented to the publication of this paper. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources for this study: No specific funding was received for this work. All potentials conflicts of interest: The authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for the Previous 12 Months: P. Fraiman reports no disclosures. R. P. C. da Hora reports no disclosures. A. J. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Abbvie, Bial, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He cofounded REGAIN Therapeutics to fund preclinical studies but relinquished the right to any personal income from future treatments. O.G.P. Barsottini reports no disclosures. J.L. Pedroso reports no disclosures. Data available on request from the authors.
DOI: 10.1002/mdc3.70227
Institutions: Universidade Federal de São Paulo, University of Cincinnati
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4412487422